Take a trial of UK to unlock this pageFind out more

Indivior

INDV 325.3p -10.1  -3.0%
4:29pm 5.00k

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2012 2013 2014 2015 2016 2017 TTM 2018E 2019E CAGR / Avg
Revenue $m
Operating Profit $m
Net Profit $m
EPS Reported $
EPS Normalised $
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps $
Capex ps $
Free Cashflow ps $
Last ex-div: 16th Jun, paid: 29th Jul more... Dividends
Dividend ps $
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc $m
Working Capital $m
Net Fixed Assets $m
Net Debt $m
Book Value $m
Average Shares m
Book Value ps $

FINANCIAL BRIEF: For the three months ended 31 March 2018, Indivior PLC revenues decreased 4% to $255M. Net income increased 16% to $93M. Revenues reflect United States segment decrease of 8% to $197M. Net income reflects Research and development expenses decrease of 36% to $16M (expense), Administrative expenses decrease of 11% to $50M (expense). Basic Earnings per Share excluding Extraordinary Items increased from $0.11 to $0.13. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
A-
A-
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 31st Mar '18) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2018
31st Dec 2019

Price Target: 4.55
(+35.81% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: -12.2% (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
7 brokers Broker Consensus Trend
Broker Recommendations for Indivior
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 2 2 3

Named Brokers and Analysts
Bank of America Merrill Lynch Graham Parry , Deutsche Bank , Stifel Nicolaus and Company, Incorporated Max Herrmann , Jefferies James Vane-Tempest , RBC Capital Markets Nicholas Keher , Morgan Stanley , Citi , Numis Securities Paul Cuddon , Cantor Fitzgerald Europe Brian White ,

Profile Summary

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia. Its products are Suboxone Film (buprenorphine and naloxone), Suboxone Tablet (buprenorphine and naloxone), and Subutex Tablet (buprenorphine). Its other products include RBP-6000 in ATRIGEL, RBP-7000 risperidone monthly depot, Arbaclofen placarbil for alcohol use disorder (AUD), Intranasal naloxone for treatment of opioid overdose and RBP-8000 cocaine esterase for cocaine intoxication. Its RBP-6000 buprenorphine monthly depot is developed for the treatment of opioid use disorder. Its RBP-7000 risperidone monthly depot is developed for treatment of schizophrenia.

Directors: Howard Pien (CHM) , Shaun Thaxter (CEO) , Mark Crossley (CFO) , Jon Fogle (CHO) , Ingo Elfering (CIO) , Christian Heidbreder (CSO) , Debby Betz (OTH) , Javier Rodriguez (OTH) , Richard Simkin (OTH) , Frank Stier (OTH) , Tatjana May (NED) 49, A. Thomas McLellan (NED) , Daniel Tasse (IND) 58, Yvonne Greenstreet (NID) , Lorna Parker (NID) ,

No. of Employees: 1,012 No. of Shareholders: n/a


Last Annual December 31st, 2017
Last Interim March 31st, 2018
Incorporated September 26, 2014
Public Since December 23, 2014
Shares in Issue 728,104,153
Free Float 724.6m (99.5%)

Address 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom
Web http://indivior.com/
Phone +44 1753 217800
Contact ()
Auditors PricewaterhouseCoopers LLP

INDV Share Price Performance INDVQuote
325.3p
-10.1  -3.0%
Traded 4:29pm · Minimum 15 min delayed · NMS: 5.00k

Latest INDV News Announcements (delayed)

Upcoming INDV Events
Wednesday 25th July, 2018
Half Year 2018 Indivior PLC Earnings Release
Wednesday 25th July, 2018
Half Year 2018 Indivior PLC Earnings Call
Monday 10th September, 2018
Indivior PLC at Morgan Stanley Healthcare Conference
Thursday 1st November, 2018
Q3 2018 Indivior PLC Earnings Release
Thursday 1st November, 2018
Q3 2018 Indivior PLC Earnings Call
Monday 3rd December, 2018 (estimate)
Indivior PLC R&D Day

Recent ↓
Tuesday 5th June, 2018
Indivior PLC at Jefferies Global Healthcare Conference
Wednesday 16th May, 2018
Indivior PLC Annual Shareholders Meeting
Tuesday 8th May, 2018
Indivior PLC at Deutsche Bank Health Care Conference
Wednesday 2nd May, 2018
Q1 2018 Indivior PLC Earnings Call
Wednesday 2nd May, 2018
Q1 2018 Indivior PLC Earnings Release
Tuesday 27th February, 2018
Indivior PLC at Credit Suisse Global Healthcare Conference
Thursday 15th February, 2018
Full Year 2017 Indivior PLC Earnings Call
Thursday 15th February, 2018
Full Year 2017 Indivior PLC Earnings Release
Thursday 11th January, 2018
Indivior PLC at JPMorgan Healthcare Conference
Thursday 11th January, 2018
Indivior PLC at JPMorgan Healthcare Conference (Q&A)
Wednesday 15th November, 2017
Indivior PLC at Jefferies Global Healthcare Conference
Thursday 2nd November, 2017
Q3 2017 Indivior PLC Earnings Call
Thursday 2nd November, 2017
Q3 2017 Indivior PLC Earnings Release
Monday 11th September, 2017
Indivior PLC at Morgan Stanley Healthcare Conference
Friday 1st September, 2017
Indivior PLC Responds To Court Rulings in ANDA Litigation and Announces Intention To Appeal Call
Thursday 27th July, 2017
Half Year 2017 Indivior PLC Earnings Call
Thursday 27th July, 2017
Half Year 2017 Indivior PLC Earnings Release
Thursday 29th June, 2017
Indivior PLC Investor Event on RBP-6000
Tuesday 6th June, 2017
Indivior PLC at Jefferies Healthcare Conference
Wednesday 17th May, 2017
Indivior PLC Annual Shareholders Meeting


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2018.


Should you buy INDV

Access INDV Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis